| __timestamp | BioCryst Pharmaceuticals, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 51796000 | 47795223 |
| Thursday, January 1, 2015 | 72758000 | 50426000 |
| Friday, January 1, 2016 | 61008000 | 70853000 |
| Sunday, January 1, 2017 | 66962000 | 78168000 |
| Monday, January 1, 2018 | 84888000 | 123757000 |
| Tuesday, January 1, 2019 | 107068000 | 140963000 |
| Wednesday, January 1, 2020 | 122964000 | 131773000 |
| Friday, January 1, 2021 | 208808000 | 210328000 |
| Saturday, January 1, 2022 | 253297000 | 235780000 |
| Sunday, January 1, 2023 | 216566000 | 244990000 |
Unleashing the power of data
In the competitive landscape of biotechnology, innovation is the lifeblood of progress. Over the past decade, Travere Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc. have been at the forefront of this innovation race, consistently investing in research and development (R&D) to drive breakthroughs.
From 2014 to 2023, both companies have shown a remarkable commitment to R&D, with Travere Therapeutics increasing its spending by over 400%, peaking in 2023. BioCryst Pharmaceuticals, not far behind, saw a similar upward trajectory, with a 300% increase in the same period. Notably, in 2021, both companies reached a pivotal moment, with R&D expenses nearly doubling from the previous year, underscoring their dedication to advancing medical science.
This trend highlights the critical role of sustained investment in R&D for biotech firms aiming to lead in innovation and deliver transformative therapies.
Comparing Innovation Spending: Novo Nordisk A/S and Travere Therapeutics, Inc.
Merck & Co., Inc. vs Travere Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Pfizer Inc. and Travere Therapeutics, Inc.
Amgen Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: argenx SE vs BioCryst Pharmaceuticals, Inc.
Analyzing R&D Budgets: Pharming Group N.V. vs Travere Therapeutics, Inc.
Research and Development Investment: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs BioCryst Pharmaceuticals, Inc.
Comparing Innovation Spending: Veracyte, Inc. and Travere Therapeutics, Inc.
Comparing Innovation Spending: Agios Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown
Who Prioritizes Innovation? R&D Spending Compared for BioCryst Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.